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ABSTRACT Aseven-valentpneumococcalconjugatevaccine(PCV7)introducedintheUnitedStatesin2000hasbeenshownto
reduceinvasivepneumococcaldisease(IPD)inbothvaccinatedchildrenandadultsthroughinductionofherdimmunity.We
assessedtheimpactofinfantimmunizationonpneumococcalpneumoniahospitalizationsandmortalityinallagegroupsusing
HealthCareUtilizationProjectStateInpatientDatabases(SID)for1996to2006from10states;SIDcontain100%samplesof
ICD9-codedhospitalizationdatafortheselectedstates.Comparedtoa1996–1997through1998–1999baseline,bythe2005–
2006season,bothIPDandpneumococcalpneumoniahospitalizationsanddeathshaddecreasedsubstantiallyinallagegroups,
includinga47%(95%conﬁdenceinterval[CI],38to54%)reductioninnonbacteremicpneumococcalpneumonia(ICD9code
481withnocodesindicatingIPD)ininfants <2yearsoldanda54%reduction(CI,53to56%)inadults >65yearsofage.A
modeldevelopedtocalculatethetotalburdenofpneumococcalpneumoniapreventedbyinfantPCV7vaccinationintheUnited
Statesfrom2000to2006estimatedareductionof788,838(CI,695,406to875,476)hospitalizationsforpneumococcalpneumo-
nia.Ninetypercentofthereductioninmodel-attributedpneumococcalpneumoniahospitalizationsoccurredthroughherdim-
munityamongadults18yearsoldandolder;similarproportionswerefoundinpneumococcaldiseasemortalitypreventedby
thevaccine.IntheﬁrstseasonsafterPCVintroduction,whenthereweresubstantialstatedifferencesincoverageamong <5-
year-olds,stateswithgreatercoveragehadsigniﬁcantlyfewerinﬂuenza-associatedpneumoniahospitalizationsamongchildren,
suggestingthatPCV7usealsoreducesinﬂuenza-attributablepneumoniahospitalizations.
IMPORTANCE Pneumoniaistheworld’sleadingcauseofdeathinchildrenandtheleadinginfectiouscauseofdeathamongU.S.
adults65yearsoldandolder.Pneumococcalconjugatevaccinationofinfantshaspreviouslybeenshowntoreduceinvasive
pneumococcaldisease(IPD)amongseniorsthroughpreventionofpneumococcaltransmissionfrominfantstoadults(herdim-
munity).Ouranalysisdocumentsasigniﬁcantvaccine-associatedreductionnotonlyinIPDbutalsoinpneumococcalpneumo-
niahospitalizationsandinpatientmortalityratesamongbothvaccinatedchildrenandunvaccinatedadults.Weestimatethat
fully90%ofthereductioninthepneumoniahospitalizationburdenoccurredamongadults.Moreover,statesthatmorerapidly
introducedtheirinfantpneumococcalimmunizationprogramshadgreaterreductionsininﬂuenza-associatedpneumoniahos-
pitalizationofchildren,presumablybecausethevaccineactstopreventthepneumococcalpneumoniathatfrequentlyfollows
inﬂuenzavirusinfection.Ourresultsindicatethatseven-valentpneumococcalconjugatevaccineusehasyieldedfargreaterben-
eﬁtsthroughherdimmunitythanhavepreviouslybeenrecognized.
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P
neumonia is not only the world’s leading cause of death
among children (1), but it is also the leading infectious cause
of death among adults (2). Immunization of infants using pneu-
mococcal conjugate vaccines has reduced invasive pneumococcal
disease (IPD) and hospitalization for pneumonia in children in
randomized trials (3–5). Since its introduction in the United
States in 2000, seven-valent conjugate pneumococcal vaccine
(PCV7) has reduced IPD dramatically, including in unvaccinated
age groups, through induction of herd immunity (6–10).
Most of the burden of pneumococcal disease, however, is not
from IPD but nonbacteremic pneumonia in adults 65 years old
and older, that is, pneumococcal pneumonia without a positive
culturefromasterilesite.Itisbiologicallyplausiblethatinterrup-
tionoftransmissionofvaccine-typeStreptococcuspneumoniaecan
reduce this burden. A groundbreaking prospective observational
study through 2004 on the Health Care Cost and Utilization
Project (HCUP) Nationwide Inpatient Sample, a 20% sample of
hospitalizations nationwide, found a signiﬁcant reduction in
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andanonsigniﬁcanttrendtowardsuchareductioninbothpneu-
mococcalandall-causepneumoniainpersons65yearsold(11).
DeWalsetal.havereportedasigniﬁcantdeclineinpneumococcal
(lobar) pneumonia in Canadian children 5 years of age after
Canada introduced the vaccine for all children in December 2004
(12), and Jardine et al. very recently reported signiﬁcant reduc-
tions in pneumococcal pneumonia in all age groups in Australia
since the vaccine was introduced there in 2005 (13).
Prevention of pneumococcal infection may also reduce hospi-
talization following inﬂuenza. Much of the pneumonia hospital-
ization burden in all age groups occurs during the winter, a fact
that has been attributed in part to bacterial pneumonia occurring
as a complication of inﬂuenza virus infection (14–17). Inﬂuenza
virusandS.pneumoniaehavebeenshowntodemonstratea“lethal
synergy” in animal models (18–20), and an analysis of an investi-
gational nine-valent conjugate pneumo-
coccal vaccine in a double-blind ran-
domized trial (21) indicated that the
rate of laboratory-conﬁrmed inﬂuenza-
associated pneumonia hospitalization
was 45% lower among vaccine recipients
than among controls.
In this paper, we describe a multipart
investigation into the effects of the intro-
duction of PCV7 on pneumonia puta-
tively caused by S. pneumoniae infection
in all age groups in the United States. We
used National Immunization Survey data
from the Centers for Disease Control and
Prevention (CDC) to estimate the grow-
ing portion of the under-5-year-old age
cohort that had been immunized in each
season. For outcome data, we obtained
complete (100%) hospitalization data
available from 10 states that were part of
the HCUP State Inpatient Databases
(SID) for the entire period of 1996
through 2006. Examining ICD9-coded
SID data, we quantiﬁed rate reductions
codedasIPD,pneumococcalpneumonia,
and all-cause pneumonia after PCV7 was
introduced. Because speciﬁc pathogens
responsible for pneumonia hospitaliza-
tions are rarely conﬁrmed, ICD9-coded
data only capture a fraction of the actual
number of cases of pneumococcal pneu-
monia. We therefore adapted modeling
techniquesusedbyinﬂuenzaepidemiolo-
gists (16, 22) to estimate the fraction of
all-cause pneumonia attributable to
S.pneumoniae,inﬂuenzavirus,andrespi-
ratory syncytial virus (RSV) infections.
We then used Poisson regression model-
ing to estimate the vaccine-associated re-
ductions in the burden of IPD, pneumo-
coccal pneumonia (directly coded and
model attributed), and all-cause pneu-
monia in the United States. Finally, we
used differences in coverage rates be-
tweenstatestoassesstheeffectofthevaccineoninﬂuenza-related
pneumonia. Our ﬁndings show that PCV7 has directly and indi-
rectlyreducedbothIPDandpneumococcalpneumonia—includ-
ing nonbacteremic pneumococcal pneumonia—in children and
adults.
RESULTS
Reductions in hospitalization rates after PVC7 introduction.
For each of 10 SID states (Arizona, Colorado, Iowa, Massachu-
setts, New Jersey, New York, Oregon, Utah, Washington, and
Wisconsin), we compared age-speciﬁc hospitalization rates for
seasons after vaccine introduction to a baseline from the three
seasons immediately before vaccine introduction (1996–1997
through 1998–1999). The SID are 100% samples of all hospital-
izationsatalltypesofhospitals.The10statesweanalyzedcontain
FIG 1 Rate ratio versus season, comparing a three-season pre-PCV7 introduction baseline outcome
rate to those of subsequent seasons for all 10 study states combined and for (A) children under 2 years
of age and (B) adults 65 years old.
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contain records of over 1 million pneumonia cases per year.
Plots of rate ratios (RRs) over time before and after the intro-
duction of PCV7 show a pattern of reductions from the baseline
for all age groups for IPD and pneumococcal pneumonia (ICD9
code481)andformostagegroupsforall-causepneumonia(ICD9
codes 480 to 486). Figure 1 shows the RRs over time for infants
2 years old and adults 65 years old. Table 1 shows the average
rates and RRs of IPD, pneumococcal pneumonia, and all-cause
pneumonia in the 10 states in the 2005–2006 season compared to
the baseline for six age groups. Figure S1 in the supplemental
material shows a representative plot of monthly pneumococcal
pneumonia hospitalizations versus season over the entire period,
in this case, for adults 65 years old (seniors) in New Jersey.
We conducted a substudy that counted patients with the 481
codebutwithnomentionofIPDcodes,indicatinghospitalization
for lobar pneumonia or nonbacteremic pneumococcal pneumo-
nia. The patients in this category accounted for ~85% of the total
numberofallpatientswiththe481codeforpneumococcalpneu-
monia, which suggests that the great majority of cases in this cat-
egory were coded on the basis of X-ray ﬁndings rather than a
bloodculturegrowingapneumococcus.Weobservedverysimilar
temporal age patterns of reduction in both outcomes (Table 1).
Note that the average incidence of cases at the baseline and in
2005–2006areaveragesofthedatafromall10states,whiletheRRs
are the means of the average RR reductions within individual
states;thus,theratesin2005–2006cannotbemultipliedbytheRR
given in Table 1 to reach the exact baseline rate.
PCV7 coverage among children <5 years old. Using an age
cohort method similar to that of Nuorti et al. (23), we analyzed
CDC National Immunization Survey data (24) to estimate the
seasonal PCV7 coverage among all children 5 years old who
either (i) had received three or more vaccine doses, with the ﬁrst
dose occurring at less than 1 year of age, or (ii) had been given
“catch-up”immunizationofoneormoredoses,withtheﬁrstdose
occurringafter1yearofage.Afterthevaccinewasintroduced,the
totalproportionofvaccinatedchildrenincreasedsteadilyinall10
states in our study, although the rate at which coverage increased
varied among these states (see Fig. S2 in the supplemental mate-
rial). We generated PCV7 coverage estimates for each season as
thegeometricmeanofthecoverageratesinthesurroundingyears
(thus,the1999–2000valuemaybeslightlyoverestimated,asmost
dosesweregiveninthesecondhalfoftheyear2000).Bythe2005–
2006 season, the coverage of children 5 years old was close to
80% in all 10 study states.
Monthly pneumonia hospitalizations attributable to S. pneu-
moniae and inﬂuenza virus. Most pneumonia patients are not
testedtodeterminethespeciﬁcpathogencausingtheirillness.The
numbers of patients given discharge diagnoses for RSV infection,
inﬂuenza, and pneumococcal pneumonia thus substantially un-
derestimate the true numbers of such events, although these val-
ues do reﬂect the epidemic patterns for these pathogens. We used
all-age monthly time series of hospitalizations ICD9 coded as any
mentioninﬂuenza,RSVinfection,andpneumococcalpneumonia
as explanatory variables to estimate the proportions of all pneu-
monia hospitalizations attributable to the three pathogens re-
sponsible in each age group in each of the 10 states. We included
RSVinthemodeltocontrolfortheeffectofthisrespiratorypatho-
gen, which is especially important among children; we do not
further analyze RSV-related hospitalization trends here.
Representative time series for attributed rates of RSV
infection- and inﬂuenza-related and pneumococcal pneumonia,
as well as the proportions of all-cause pneumonia attributed by
the model to the pneumococcus are shown in Fig. 2; representa-
tive model ﬁts are shown in Fig. S3 in the supplemental material.
As expected, our model found greater attributions of RSV in chil-
dren(Fig.2A)andinﬂuenzavirusinseniorsintermsofincidence
rates (Fig. 2B).
PCV7-associated reductions in the burden of hospitaliza-
tions for pneumococcal disease. We applied Poisson regression
modeling techniques to monthly time series of hospitalization
data from 10 SID states for the 1996–1997 through 2005–2006
seasons and found statistically signiﬁcant associations of PCV7
coverage with decreases in hospitalization rates for IPD, Interna-
tional Statistical Classiﬁcation of Diseases and Related Health
Problems (ICD)-coded pneumococcal pneumonia, model-
attributed pneumococcal pneumonia, and all-cause pneumonia
inallagegroups.WethenusedU.S.censusdataandthemodeling
results—speciﬁcally,ourestimatesofthereductioninhospitaliza-
tions associated with incremental increases in vaccine cover-
age—toestimatethetotalreductionsinthepneumococcaldisease
hospitalization burden associated with PCV7 vaccine use in the
United States since the vaccine was introduced (Table 2). In per-
centage terms, the IPD burden declined the most sharply. The
TABLE 1 Annual hospitalization rates per 100,000 in the pre-PCV7 period in the 10 study states at baselinea and in the 2005–2006 season
Age
(yr)
Rate of IPD cases
RR
(95% CI)
Rate of
pneumococcal
(lobar)
pneumonia cases
(ICD9 481)
RR
(95% CI)
Rate of
nonbacteremic
pneumococcal
pneumonia cases
(ICD9 481 with
no IPD code
RR
(95% CI)
Rate of all-cause
pneumonia cases
RR
(95% CI) Baseline
2005–
2006 Baseline
2005–
2006 Baseline
2005–
2006 Baseline
2005–
2006
0-1 27.8 5.5 0.20 (0.16–0.24) 25.9 13.4 0.49 (0.43–0.58) 22.1 12.4 0.53 (0.46–0.62) 1,026.5 753.7 0.72 (0.70–0.73)
2–4 5.4 2.0 0.35 (0.27–0.47) 11.8 9.1 0.83 (0.72–0.96) 10.5 8.5 0.88 (0.76–1.02) 307.5 303.4 0.99 (0.96–1.01)
5–17 1.4 0.7 0.47 (0.36–0.60) 4.9 2.6 0.52 (0.46–0.59) 4.4 2.4 0.54 (0.47–0.62) 76.1 67.0 0.87 (0.85–0.90)
18–39 3.5 1.4 0.38 (0.34–0.43) 11.6 4.3 0.37 (0.35–0.40) 9.4 3.5 0.39 (0.36–0.42) 88.5 62.6 0.68 (0.67–0.70)
40–64 8.9 6.0 0.64 (0.60–0.68) 30.2 16.6 0.56 (0.54–0.58) 24.8 13.6 0.56 (0.54–0.58) 250.9 234.6 0.92 (0.91–0.93)
65 30.6 17.1 0.53 (0.50–0.56) 144.9 64.7 0.46 (0.44–0.47) 126.1 55.9 0.46 (0.44–0.47) 1,875. 2 1672. 6 0.88 (0.87–0.89)
a 1996–1997 through 1998–1999 seasons.
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and nonbacteremic pneumococcal pneu-
moniaalsodeclinedsigniﬁcantlyinallage
groups. We found statistically signiﬁcant
reductionsinall-causepneumoniahospi-
talization in three age groups (infants
2 years old, 5 to 17 year olds, and 18 to
39yearolds)andnosigniﬁcantreduction
in the population as a whole. Note that
the relative rates given in Tables 1 and 2
are not directly comparable. Table 1 pro-
vides rates in the 2005–2006 season alone
relative to the baseline, whereas the mod-
eled reductions are cumulative across all
ofthestudyyearsandthuslesssensitiveto
variability in individual study years, ex-
plaining, for example, the apparent dis-
crepancy between the 40- to 64-year-old
age group results in the two tables.
PCV7-associated reductions in the
burden of in-hospital mortality with
pneumococcal disease. To assess the
mortality burden changes, we used the
discharge status variable to ﬁnd events
where the patient had died while hos-
pitalized. Using a similar Poisson model-
ing approach but seasonal rather than
monthlydata(becausethenumbersofin-
hospital deaths were much smaller), we
foundsigniﬁcantassociationsofincreases
in PCV7 coverage with reductions in in-
hospitalmortalityforIPD,pneumococcal
pneumonia,andall-causepneumoniadi-
agnoses (Table 3). Because in-hospital
deaths due to pneumococcal, inﬂuenza
virus, and RSV infections are rare out-
comes in most age groups, we did not
havesufﬁcientdatatomodelthemonthly
mortality time series, a necessary step in
estimating attributed pneumococcal pneu-
monia mortality.
PCV7-associated reductions in all-
cause pneumonia hospitalizations at-
tributabletoinﬂuenzavirus.Theburden
of inﬂuenza virus-attributable pneumo-
nia varies substantially from season to
season, depending on the characteristics
of the strains that dominate each season.
The seasons 1999–2000 through 2002–
2003 were dominated by seasonal A/H1N1
or inﬂuenza virus B strains and were rel-
ativelymildcomparedtothebaselinesea-
sons. However, A/H3N2 strains domi-
nated the 2003–2004 and 2004–2005
seasons, resulting in a sharp increase in
the number of inﬂuenza-related pneu-
monia hospitalizations; these increases
are reﬂected in Fig. 2. This variability,
unrelated to the PCV7 vaccination pro-
gram,hamperedourabilitytomodeltime
FIG 2 Representative plots of rates of all-cause pneumonia (ICD9 codes 480 to 486, grey) and model
attributionsforRSV-relatedpneumonia(green),pneumococcalpneumonia(red),andinﬂuenzavirus-
related pneumonia (light blue). Data shown are from New Jersey for (A) children under 2 years of age
and (B) adults 65 years old; panel C shows the proportion of all-cause pneumonia attributed by our
model to the pneumococcus.
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to PCV7 use.
So, instead, we looked for single-season associations between
state PCV coverage rates and changes in IPD and attributed
inﬂuenza-relatedpneumoniahospitalizationrates,foreachofthe
seasons 2000–2001 through 2003–2004 and compared to a pre-
vaccinebaseline.Forattributableinﬂuenza-relatedpneumoniain
infants 2 years old, higher rates of coverage by state were signif-
icantlyassociatedwithareduceddiseaseburdeninallfourseasons
(Fig. 3); among seniors, we found negative associations in all sea-
sons,althoughtheseweresigniﬁcantonlyinthe2002–2003season
(Table 4). For IPD, we found a negative association between inci-
dence and PCV7 coverage by state in all four seasons for children
2yearsofage;however,thisnegativeassociationwassigniﬁcant
only for the 2001–2002 and 2002–2003 seasons; among seniors,
thetrendwasnegativeinallseasonsexcept2000–2001butwasnot
signiﬁcant in any season (see Fig. S4 in the supplemental mate-
rial).
Residual hospitalization and mortality burden in 2006. In
the2005–2006season,theresidualhospitalizationburdenamong
children less than 2 years old was 5.5 IPD cases per 100,000, 12.4
nonbacteremic ICD9 481 cases per 100,000, and 115 model-
attributed pneumonia cases per 100,000. The remaining burdens
among persons 65 years old and older were, of course, consider-
ably higher: 17.1 IPD cases per 100,000, 55.9 noninvasive ICD9-
codedcasesper100,000,and271.7model-attributedpneumococ-
cal pneumonia cases per 100,000. For in-hospital mortality, the
residual burden among infants 2 years old was 0.2 IPD and 0.2
noninvasiveICD9code481casesper100,000.Theremainingbur-
dens among persons 65 years old and older were 2.8 IPD and 3.5
noninvasive ICD9-coded cases per 100,000.
DISCUSSION
It has been demonstrated repeatedly that PCV7 has substantially
reduced IPD among vaccinated children. Our data extend these
observations to show signiﬁcant reductions in IPD and pneumo-
coccalpneumoniainallagegroups.Ourmodelingresultsindicate
that the vaccine has prevented nearly 800,000 hospitalizations for
pneumococcal pneumonia in the United States during the period
from 2000 to 2006. We note that 90% of the model-attributed
pneumococcal pneumonia and 95% of the nonbacteremic pneu-
mococcal pneumonia reductions were in adults 18 years old.
These data show that indirect effects were responsible for most of
the burden of pneumococcal disease prevented, although a sub-
stantial burden of both lobar and all-cause pneumonia remains.
ThereductionsinIPDwefoundin10statescorrespondclosely
toobservationsbasedondatafromtheCDCActiveBacterialCore
(ABC)surveillancesites(9).By2006,wefoundreductionsof80%
and 65% in all-serotype IPD among infants 2 years old and
children2to4yearsold,respectively,whilePilishvilietal.founda
reduction of 76% among all children 5 years old. Similarly, for
adults 65 years old, we found a reduction of all-serotype IPD of
47%by2006,whilePilishvilietal.reportedareductionof37%by
2007. This gives us conﬁdence that using ICD-coded data can
produce results similar to those of studies using laboratory-
conﬁrmedcasesonly.Moreover,Pilishvilietal.alsoobservedthat
TABLE 3 Estimated PCV7-associated reductionsa in the U.S. burden of mortality while hospitalized for IPD, pneumococcal pneumonia, or
all-cause pneumonia, 1999–2000 through 2005–2006 seasons
Age
group
Estimated
IPD reduction 95% CI
Estimated
pneumococcal pneumonia
(ICD9 481) reduction 95% CI
Estimated all-cause
pneumonia reduction 95% CI
2 212 81–275 34 –66–67 548 425–646
2–4 46 12–62 26 –3–38 191 136–235
5–17 103 65–130 13 –14–29 350 252–431
18–39 810 674–922 1,088 888–1,245 2,495 2,220–2,754
40–64 1,045 709–1,349 2,304 1,990–2,596 8,513 7,674–9,312
65 4,007 3,246–4,693 10,895 9,772–11,934 71,556 61,644–81,013
Total 6,222 4,788–7,431 14,360 12,568–15,908 83,653 72,351–94,391
a Number of deaths prevented.
TABLE 2 Estimated PCV7-associated reductionsa in the U.S. burden of hospitalizations for various pneumococcal pneumonia outcomes,
1999–2000 through 2005–2006 seasons
Age
group
Estimated
IPD
reduction 95% CI
Estimated
pneumococcal
(lobar)
pneumonia
(ICD9 481)
reduction 95% CI
Estimated
nonbacteremic
pneumococcal
pneumonia
(ICD9 481
with no
IPD codes)
reduction 95% CI
Estimated
attributed
(model-derived)
pneumococcal
pneumonia
reduction 95% CI
Estimated
all-cause
pneumonia
reduction 95% CI
2 8,440 8,101–8,752 4,437 3,550–5,216 3,399 4,119–2,572 36,442 31,928–40,667 80,494 56,295–103,022
2–4 2,025 1,766–2,244 1,442 741–2,067 934 1,590–188 2,540 2,156–2,899 3,920 16,325–7,818
5–17 1,528 1,257–1,772 4,544 3,863–5,170 3,977 4,595–3,305 38,211 35,064–41,187 8,879 368–17,121
18–39 8,592 7,658–9,432 28,344 26,324–30,249 21,808 23,411–20,094 86,925 74,592–97,881 82,299 47,421–113,857
40–64 7,270 5,428–9,004 30,536 27,469–33,450 24,614 26,976–22,169 122,239 104,095–139,195 35,071 71,505–530
65 20,046 16,851–23,014 113,789 101,965–124,905 99,415 110,428–87,565 502,482 447,571–553,546 62,987 50,803–173,014
Total 47,899 41,060–54,218 183,093 163,911–201,057 154,147 171,118–135,893 788,838 695,406–875,376 195,668 34,550–414,303
a Cumulative number of cases prevented since vaccine introduction.
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serotypes of S. pneumoniae in the vaccine; this key observation
providesstrongevidencethatthevaccineinfactcausedthereduc-
tions demonstrated here. Our analysis, however, cannot separate
vaccine-type reductions from non-vaccine-type disease because
ICD9codesarenotstrainspeciﬁc.Althoughthepatternofreduc-
tions in IPD incidence in our study reﬂects that observed in the
CDC’spopulation-basedABCsurveillancedata,thebaselinerates
TABLE 4 Modeled rate reductions per 10 percentage point increase in PCV7 coverage for two age groups
Season
Estimated reduction (95% CI)
IPD Model-attributed inﬂuenza-related pneumonia
2-yr-old group 65-yr-old group 2-yr-old group 65-yr-old group
2000–2001 0.84 (0.51–1.39) 1.09 (0.87–1.35) 0.50 (0.29–0.85) 0.91 (0.75–1.12)
2001–2002 0.77 (0.60–0.98) 0.94 (0.76–1.15) 0.61 (0.39–0.96) 0.85 (0.66–1.11)
2002–2003 0.75 (0.62–0.90) 0.96 (0.83–1.12) 0.53 (0.36–0.78) 0.80 (0.67–0.96)
2003–2004 0.82 (0.62–1.09) 0.93 (0.78–1.11) 0.59 (0.37–0.92) 0.68 (0.41–1.15)
FIG3 ScatterplotsofstatehospitalizationRRs(season/baseline)versusstatePCVcoverageforthe1999–2000throughthe2003–2004seasonsfor(A)attributed
inﬂuenza-related pneumonia among those 2 years old and (B) attributed inﬂuenza-related pneumonia among those 65 years old. The lines represent
exponential ﬁts to the data from each season, showing the trend. An asterisk next to the year in each panel indicates a signiﬁcant trend.
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cases/100,000 in adults 65 years old) are lower than those re-
ported in the ABC study (56.8 and 60 cases/100,000, respectively)
for the same time period (6). Unlike the ABC sites, no audit is
possible in our study to identify missed cases. Our estimates of
hospitalized patients with IPD therefore represent an underesti-
mate of the true burden due to this condition.
Grijalva et al. (11) studied trends in pneumococcal and all-
causepneumoniaratesbeforeandaftertheyear2000.Theyattrib-
utedthechangingtrendsintheseoutcomesbeforeandafterPCV7
introduction to the beneﬁts of the vaccine (11, 25). They found
that introduction of PCV7 vaccine coincided with declines in
pneumococcalpneumoniaratesininfants2yearsold.Theyalso
found a trend toward a reduction in pneumococcal pneumonia
rates in adults 65 years old, although it was not statistically sig-
niﬁcant.However,whiletheydidobserveareductioninpneumo-
coccalpneumoniahospitalizationsininfants2yearsold,among
children 2 to 4 years old, this reduction was signiﬁcant in 2004
(11)butnolongersoin2006(25),eventhoughthisagegrouphad
achieved high PCV7 coverage by 2006. We found the lowest re-
duction(17%)inpneumococcalpneumoniainthisagegroupand
a nonsigniﬁcant reduction of 12% when bacteremic cases were
excluded. The pneumococcal types included in PCV7 decrease in
frequency after 2 years of age, and the proportion of nonvaccine
types is therefore greater above that age (26). Children who get
pneumonia at 2 to 4 years of age tend to have a greater frequency
of risks, such as group child care. These risks continue to make
them susceptible to non-PCV7 types, so that replacement disease
has a larger impact on this age group than on infants 2 years of
age (27). Nelson et al. conducted a comprehensive, population-
based evaluation of trends in pneumonia and inﬂuenza (P&I)
rates in a health maintenance organization population and found
a nonsigniﬁcant 40% decline in the rates of hospitalization of in-
fants for community-acquired pneumonia from 1998 to 2004,
withnoconsistentevidenceofadeclineinadultratesandthusno
evidenceofindirectPCV7beneﬁts(28).However,thisstudywasof
a smaller population (~800,000), and the severe 2003–2004 Fujian
A/H3N2inﬂuenzaseasonlikelyledtoincreasedP&Iratesinthepost-
PCV period and an underestimation of vaccine program beneﬁts.
Our study extends these ﬁndings using a longer time series,
100% state inpatient data, and all identiﬁed (not just primary
diagnosis) cases. It also introduces a novel modeling approach to
overcome the nonspeciﬁcity of the all-cause pneumonia end-
point, with the result that we ﬁnd signiﬁcant reductions in pneu-
mococcal pneumonia in all age groups after the PCV7 launch in
theUnitedStates.Aprimarygoalofourinvestigationwastotease
out the speciﬁc effects of PCV7 vaccination on pneumococcal
pneumonia rates. In particular, we wanted to look at the age-
speciﬁc effect of the vaccine on the total pneumococcal pneumo-
niaburden,includingboththe“tipoftheiceberg”thatisindicated
by the ICD9 481 code and the much larger “under-the-waterline”
portion that, although caused by S. pneumoniae infection, is not
diagnosedassuch.Webelievethatmodel-attributedpneumococcal
pneumonia,beingmorespeciﬁctoS.pneumoniaeinfection,isamore
tellingoutcomethanall-causepneumonia,whichisaffectedbymany
viral and bacterial infections that PCV7 cannot prevent.
To attribute the pneumococcal pneumonia portion of all-
cause pneumonia, we adapted statistical methods that inﬂuenza
epidemiologistshavelongusedtoattributeaportionofthewinter
rise in pneumonia hospitalizations and deaths to inﬂuenza (29–
31). Speciﬁcally, we modiﬁed the approach of Thompson et al.
(16), which relied on the time pattern of laboratory-conﬁrmed
illness due to RSV and inﬂuenza virus to estimate the portion of
hospitalizationsrelatedtoinﬂuenza(16).We,however,usedICD-
coded hospitalizations speciﬁc to respiratory pathogens and in-
cluded hospitalizations due not only to inﬂuenza virus and RSV
infections but also to pneumococcal pneumonia. In this regard,
we followed Pitman et al. (22) in that we included time patterns
for multiple pathogens to attribute a portion of the observed all-
cause pneumonia pattern to each pathogen. Doing so allowed us
to estimate the proportion of all-cause pneumonia attributable to
S. pneumoniae infection while controlling for pneumonia associ-
ated with the other two pathogens.
Regarding our modeling of the reductions in burden, with the
exception of all-cause pneumonia, we found signiﬁcant reduc-
tions in hospitalizations for each age group and for each outcome
(IPD and observed and model-attributed pneumococcal pneu-
monia) across all age groups, with patterns very much like those
estimatedfromABCdataderivedfromlaboratory-conﬁrmedIPD
cases. For all-cause pneumonia, however, we found a signiﬁcant
burden reduction only among infants 2 years old and a nonsig-
niﬁcantreductionof200,000hospitalizationsacrossallagegroups
(Table 2). We attribute this result to the fact that all-cause pneu-
monia is the least speciﬁc outcome analyzed and particularly sus-
ceptible to variability in inﬂuenza severity between seasons. For
example,acrossallagegroupsatthebaseline(1996–1997through
1998–1999), our model attributes ~30% of what is coded as all-
causepneumoniatopneumococcalinfectionand7%toinﬂuenza
across all age groups.
Another goal of our investigation was to assess the effect of
PCV7 on inﬂuenza-related pneumonia. The variability of inﬂu-
enzaseasonseverityconfoundedourtimeseriesmodelingefforts.
We therefore studied state differences in inﬂuenza-attributed
pneumonia within single seasons, taking advantage of between-
statedifferencesinPCV7coverageupthroughthe2003–2004sea-
son, when the recommendation for inﬂuenza immunization was
extended to children and 10% of young children were fully im-
munized against inﬂuenza (32). We used a Poisson regression
technique to evaluate whether, for each age group and season,
states with higher coverage had signiﬁcantly greater reductions
than those with lower coverage. Because we included the baseline
of each state and age group as a covariate, each acted as its own
control for bias resulting from interstate differences in socioeco-
nomic status and other potential confounders.
In these single-season analyses, we found that reductions in
model-attributed inﬂuenza-related pneumonia hospitalization
were signiﬁcantly associated with higher PCV7 coverage for the
ﬁrst four seasons after vaccine use began; although the trend was
toward reduction among seniors, the results were not signiﬁcant
(Table 4). The window of time within which there was signiﬁcant
variance between states in PCV coverage and before there was
widespreadherdimmunitytothePCV7typesintheUnitedStates
was limited to these seasons. During this time, we see an associa-
tion of 10% PCV7 coverage variance with signiﬁcant 39 to 50%
reductionsininﬂuenza-associatedpneumoniaininfants2years
old. This is similar in magnitude to the observation of a 45%
reduction in inﬂuenza-associated pneumonia hospitalization
among African infants 2 years old who received PCV9 vaccina-
tion in an environment in which the PCV9 types accounted for
onlyhalfofthetypescausingdiseaseinthatagegroup(21).These
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hospitalizations in this age group may be due to pneumococcal
coinfection.
Althoughtheassociatedreductionswithinﬂuenzaareencour-
aging, we also note that the model failed to detect signiﬁcant re-
ductions for IPD in seniors (column 2, Table 4) although ABC
datahaveshownitandwehavealreadydemonstrateditinTable1
andFigure1.Thiswaslikelytheresultofinstabilityofthemodelas
only few datapoints were available for single-year analysis. Al-
though the estimates for rate reductions in IPD produced by our
single-year analysis have wide conﬁdence intervals (CIs), the esti-
matesagreereasonablywellwiththoseproducedbyourmultiyear
model, namely, 0.81 and 0.93 for the youngest and oldest age
groups, respectively, per 10 percentage point increase in PCV7
coverage. This helps to increase our conﬁdence in our model-
attributed inﬂuenza-related pneumonia results.
We recognize at least three potential limitations of our study.
First, we relied on ICD9 codes for the status of the inpatients we
studied. The cases were not ascertained by medical chart review,
and thus, our approach assumes that physicians assigned ICD9-
coded diagnoses correctly. Speciﬁcally, since ICD9 code 481 is
indicatedforcasesofS.pneumoniaeorlobarpneumonia,wecan-
not know whether the doctor reached that conclusion from labo-
ratory testing, X-ray results, or clinical judgment; however, be-
cause the temporal trend resembles that of IPD in our study, we
canarguethatthe481codeiscapturingthe“groundtruth”reduc-
tion in pneumococcal disease. Moreover, because only a small
subset(10to20%)ofallrecordswithICD9code481alsohaveIPD
codes,wecanassumethatinmostcasesICD9code481represents
clinical lobar pneumonia rather than microbiologically deﬁned
pneumococcal pneumonia.
Second, the method we used to attribute a portion of all-cause
pneumonia to S. pneumoniae infection (Poisson regression mod-
eling) assumes that the trends and patterns in the ICD-coded ex-
planatory variables changed over time only as a result of vaccine
effectiveness. If, for example, the PCV7 program had caused phy-
sicians to become less likely to diagnose S. pneumoniae infection
anduseICD9code481—becausetheysubmittedsamplesfortest-
inglessfrequentlyafterthevaccinewasintroduced,forexample—
then the model would tend to overestimate the beneﬁts of the
PCV7program.Althoughthisphenomenonmayhaveoccurredin
outpatient settings, we think it less likely for the diagnosis of in-
patients, because hospital physicians may be more responsive to
medical and economic imperatives to order laboratory testing to
determine the etiology of their patients’ illnesses.
Third,wedidnottakeintoaccountagingwithintheseniorage
group;anincreasingpercentageofseniorsareover80yearsofage,
andtheriskofpneumoniahospitalizationincreaseswithage.This
may explain, in part, the ﬁnding that the all-cause pneumonia
hospitalization rate did not decrease over time in the oldest age
group(Fig.1B).Thus,bynotcontrollingtightlyforageinpersons
over 65, we may have underestimated the true beneﬁts of the vac-
cine program for seniors in terms of all-cause pneumonia reduc-
tion. For the more speciﬁc outcomes like IPD and S. pneumoniae
pneumonia (ICD9 code 481), this is less of a problem in that the
estimated reduction is profound.
In early 2010, a new 13-valent version of the vaccine (PCV13)
was introduced in the United States with the promise of further
reducingtheresidualburdenofpneumococcaldisease.According
to our study, in the 2005–2006 season, there was a residual hospi-
talization burden of 5.5 IPD cases, 12.4 noninvasive ICD9 481
cases, and 115 model-attributed pneumococcal pneumonia cases
per 100,000 among children less than 2 years of age, with consid-
erablyhigherresidualburdensamongadults.Weplantocontinue
to follow these rates in years to come, in order to assess the mag-
nitude and sustainability of the disease burden reduction follow-
ing PCV13 introduction.
The ability of PCV7 to induce herd immunity invites a discus-
sion of how best to protect seniors, a group that does not respond
as well to vaccination because of immune senescence or underly-
ing illness. Although PCV7-vaccinated children accounted for
only ~5% of the U.S. population by 2006, our study suggests that
this was sufﬁcient to reduce the burden of pneumococcal disease
substantially in all age groups. Our results further suggest that
more than 90% of the prevention of hospitalizations and deaths
due to pneumonia attributable to the vaccine occurred among
patients 18 years old, and most of this occurred among those
65 years old. There is evidence that this group has not been well
protectedbydirectimmunizationwitheitherthe23-valentpneumo-
coccal vaccine (33) or inﬂuenza vaccine (34–37). It is possible that
indirectprotection(herdimmunity)throughvaccinationofchildren
will more effectively protect seniors against pneumococcal disease.
Immunization with PCV7 in the United States has led to pro-
found reductions in the disease burden among adults in the ﬁrst
7 years of the program. Whether this continues to be the case in
the future should be monitored carefully due to the possibility of
strain replacement. Whether the U.S. experience can be extrapo-
lated to other countries remains to be seen. The different patterns
of social mixing, overcrowding, and residual carriage of vaccine
types among HIV-infected infants (38) all demand caution in ex-
trapolating these observations to developing countries, where
studiesonherdimmunityinducedbyPCVintroductionwillbean
essential part of vaccination impact measurement.
MATERIALS AND METHODS
Datasources.TheHCUPmaintainsSIDfrommanyU.S.states(39).The
annual state-speciﬁc SID ﬁles contain data elements in a uniform format,
and most ﬁles contain data on a state’s total hospital discharges coded
accordingtotheICD.WebasedouranalysisonavailableSIDdatafrom10
states for 1996 to 2006 that provided the admission month and the age in
years. Because SID data have no personal identiﬁers, this study is exempt
from Institutional Review Board consideration.
The CDC National Immunization Survey (NIS) collects vaccination
histories for children 19 to 35 months old to estimate national and state
level vaccination coverage for many vaccines, including PCV7. We used
NIS public use SAS data ﬁles available at the CDC website to estimate
vaccine coverage in children5 years old in each state and for each study
season (24).
We used U.S. Census Bureau estimates of yearly U.S. age- and state-
speciﬁc populations to denominate the number of hospitalizations for
each outcome. We performed all statistical analyses with SAS statistical
software version 9.2 (SAS Institute Inc., Cary, NC). We deﬁned each sea-
son as July of one year through June of the next.
PCV7coverageestimates.Wedevelopedanagecohortmodelstrategy
similar to that of a recent CDC study (23) to convert detailed survey
information into corrected historic vaccine uptake. We estimated vacci-
nation coverage rates by 1-year infant age cohort for each calendar year
and then summed these to compute PCV7 coverage for all children 0 to
59 months old, deﬁning as covered all children who received either three
or more doses, with the ﬁrst occurring at 1 year of age, or one or more
catch-up doses, with the ﬁrst occurring at 1 year of age. We converted
these annual coverage estimates to seasonal estimates for the 1999–2000
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years (e.g., we took the average of the 2002 and 2003 coverage to arrive at
the coverage for the 2002–2003 season).
ICD9-coded outcome deﬁnitions and rate comparisons. For each
state and season, we extracted the numbers of hospitalizations for each
outcome from among all of the listed diagnosis codes. We deﬁned IPD as
ICD9 code 320.1 or 038.2 or as codes 320.8, 790.7, or 038.9 and 041.2;
pneumonia with diagnosed S. pneumoniae infection as ICD9 code 481;
andall-causepneumoniaasICD9codes480to486.Nonbacteremicpneu-
mococcal pneumonia cases were deﬁned as those with any mention of an
ICD9 code 481 diagnosis but without mention of a diagnosis of IPD as
deﬁned above. We scanned across discharge diagnoses in each patient
record for any mention of these disease codes. We used the disposition
informationatdischargetoidentifythesubsetofhospitalizationsforeach
outcome that resulted in inpatient death. We constructed time series of
each outcome for each state and for six age groups, 2 years old, 2 to
4 years old, 5 to 17 years old, 18 to 39 years old, 40 to 64 years old, and
65yearsold.BaselineratesbeforeintroductionofPCV7weredeﬁnedas
the average annualized rates during the 1996–1997 through 1998–1999
seasons; incidence RR estimates and 95% CIs were calculated using
outcome-speciﬁc Poisson regression models.
Attributing pneumococcal and inﬂuenza-associated pneumonia
hospitalizations.Becauseinﬂuenzavirusinfectionisrarelyconﬁrmedby
laboratory testing and because a triggering inﬂuenza virus infection is
often resolved by the time a patient presents with secondary complica-
tions such as bacterial pneumonia, it is not possible to directly assess the
inﬂuenza disease burden. Modeling the pediatric burden of inﬂuenza is
further complicated by the concurrent impact of RSV during winter
months. Moreover, because most pneumonia hospitalizations are not
linked to a speciﬁc pathogen, pneumonia due to infection with S. pneu-
moniae is frequently not recorded as such on hospital discharge forms.
Toovercometheselimitations,weappliedaPoissonregressionmodeling
strategytomonthlytimeseriesofoutcomeincidencesper100,000inorderto
estimate the seasonal inﬂuenza-related and pneumococcal pneumonia-
associatedburdensinoursixagegroups.Ourstrategywassimilartothatused
by Thompson et al. (16) to assess inﬂuenza-related pneumonia. However,
instead of weekly laboratory virus surveillance data for inﬂuenza and RSV
epidemic patterns, we used ICD9-coded counts of inﬂuenza (ICD9 487, any
mention)andRSVinfection(ICD9480.1,anymention)asexplanatoryvari-
ables, similar to Pitman et al. (22); we also included S. pneumoniae pneumo-
nia (ICD9 481, any mention) as a third explanatory respiratory pathogen
variable.Alineartrendandasinusoidalwavecomponentaccountedforsea-
sonalityandseculartrendsnotcapturedbythe“pathogen”explanatoryvari-
ables. The best-ﬁtting model was of the form
AC pneumonia  exp 0  1month  2influenza  3RSV
 4pneumococcus  5sin2t/12  6cos2t/12
where AC pneumonia is all-cause pneumonia, deﬁned as ICD codes 480
to486astheprimarycause(removingrecordswithﬁrst-listedICD9codes
of 480.1 and 481); inﬂuenza (ICD code 487), RSV (ICD code 480.1), and
pneumococcus (ICD code 481) are the monthly rates of hospitalizations
speciﬁcallyassociatedwitheachoutcomeineachstate(allages,anymen-
tion); and month is the running month variable. The cyclical terms track
additional seasonality in the pneumonia data.
We computed fractions of all-cause pneumonia attributed to inﬂu-
enza virus, RSV, and S. pneumoniae for all available state/age group time
series. For most state/age group combinations, all of the variables in the
model were signiﬁcant. However, we did not change the model form to
accommodatestatesoragegroupsincaseswherenotallexplanatoryvari-
ablesweresigniﬁcantattheP0.05level.Ifanyparametervaluewasless
than zero, we set the number of attributed cases to zero. And ﬁnally, we
summedthemodelattributionandtheICD9-codedattributiontogener-
ate the total attributed fraction of all-cause pneumonia to S. pneumoniae,
RSV,andinﬂuenzavirus,respectively.FigureS3inthesupplementalma-
terial shows a typical model ﬁt, here for data from children 2 to 4 years of
age in New Jersey.
Modeling reductions in pneumococcal disease burden associated
with PCV7 use. We ﬁrst constructed Poisson regression models to assess
the effect of PCV7 coverage on hospitalization and in-hospital mortality.
We analyzed time series extracted from SID data from 10 states spanning
the 1996–1997 through 2005–2006 seasons, with the exception of Utah,
for which data were unavailable for the 1996–1997 season. We con-
structedtimeseriesforsixagegroups,youngerthan2yearsold,2through
4 years old, 5 through 17 years old, 18 through 39 years old, 40 through
64 years old, and 65 years old or older. RRs and accompanying 95% CIs
were calculated to represent the association between 10 percentage point
increments in PCV7 coverage and outcome rates.
For hospitalization rates, we ran age-speciﬁc Poisson regressions on
monthly time series for each state and age group. The model form that
best ﬁt the data was
Y/Nexp{01[sin(2t⁄12)]2[cos(2t/12)]3(PCV)}
whereYisthenumberofhospitalizationsduringaparticularmonthfora
speciﬁcagegroup,Nisthepopulationoffset,andtisthecalendarmonth,
0 yielded the intercept while 1 and 2 accounted for seasonal changes
in hospitalizations and 3 accounted for the effect of PCV7 coverage in
children5yearsold.Forin-hospitalmortalityrates,weappliedthesame
model form to seasonal counts of cases in which a patient had both a
diagnosis code associated with each outcome and a discharge status code
indicating that the patient died in the hospital.
We used the results of these analyses to estimate cumulative national
reductions in disease and mortality burdens associated with PCV7 use in
each age group. For each outcome, we ﬁrst used U.S. census data and the
aggregate seasonal rates for the 1996–1997 through the 1998–1999 sea-
sonsfrom10statestoestimatethenationalburden.Then,foreachseason
and age group, we used national PCV7 coverage, the RR per percentage
point increment in coverage, and U.S. census data to estimate the PCV7-
associated change in burden for each season and summed these reduc-
tions for the 1999–2000 through the 2005–2006 seasons.
Single-season analysis of IPD and model-attributed inﬂuenza-
relatedpneumonia.UsingSIDdatafrom10statesforeachagegroup,we
determined the ratio of the rates of IPD and model-attributed inﬂuenza-
related pneumonia in each post-PCV7 season compared to a baseline
determined by the average of rates in the 1996–1997 through the 1998–
1999 seasons. We then used Poisson regression to model the relative rate
reduction associated with a 10 percentage point increase in PCV7 cover-
ageandcalculatedtwo-sidedPvaluestotestthehypothesisofnoeffectof
vaccination.
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